Miravitlles M, et al. - Via a systematic review and meta-analysis, the tiotropium (TIO)/olodaterol (OLO) combination was appraised as a treatment option for chronic obstructive pulmonary disease (COPD) patients, in terms of efficacy and safety. The evidence demonstrated that in comparison to mono-components and long acting beta-agonists (LABA) /ICS, treatment with TIO/OLO afforded significant improvements in lung function; more patients achieved significant improvements in dyspnea and health status. Furthermore, TIO/OLO-related adverse events did not differ as compared with other active treatments.